Hikma Pharmaceuticals (HIK)

Sector:

Pharma and Biotech

Index:

FTSE 100

1,939.00p
   
  • Change Today:
    -2.00p
  • 52 Week High: 2,205.00p
  • 52 Week Low: 1,722.00p
  • Currency: UK Pounds
  • Shares Issued: 221.89m
  • Volume: 34,783
  • Market Cap: £4,302.36m
  • RiskGrade: 125

ShareCast News

Hikma gets FDA approval for generic version of '... 22-May-2020 ShareCast
Sunday newspaper round-up: Sovereign wealth fund... 17-May-2020 ShareCast
Hikma confident on outlook as sales rise in crisis 30-Apr-2020 ShareCast
Friday broker round-up 24-Apr-2020 ShareCast
Friday broker round-up 03-Apr-2020 ShareCast
JP Morgan ups rating on Hikma after key patent win 02-Apr-2020 ShareCast
Thursday broker round-up 02-Apr-2020 ShareCast
Hikma wins US patent case 31-Mar-2020 ShareCast
Hikma posts decent results as it signs 'Ryaltris... 27-Feb-2020 ShareCast
Thursday broker round-up 20-Feb-2020 ShareCast
Monday broker round-up 17-Feb-2020 ShareCast
Hikma inks exclusive agreement with Chiesi Farma... 13-Jan-2020 ShareCast
Friday broker round-up 10-Jan-2020 ShareCast
Hikma, Arecor to co-develop injectable medicine ... 09-Jan-2020 ShareCast
Hikma responds to FDA concerns over 'Advair Disk... 27-Nov-2019 ShareCast
Hikma Pharmaceuticals maintains guidance as it i... 07-Nov-2019 ShareCast
FTSE 250 movers: Sirius plummets, Sophos climbs 17-Sep-2019 ShareCast
M&S faces FTSE 100 demotion for the first time 23-Aug-2019 ShareCast
Hikma Pharmaceuticals raises generics guidance a... 09-Aug-2019 ShareCast
Wednesday broker round-up 01-Aug-2019 ShareCast
Hikma signs exclusive agreement with Richter for... 25-Jul-2019 ShareCast
Hikma reports good start to 2019 17-May-2019 ShareCast
Wednesday broker round-up 10-Apr-2019 ShareCast
Hikma Pharmaceuticals director buys-in after ful... 14-Mar-2019 ShareCast
Thursday broker round-up 14-Mar-2019 ShareCast
Hikma Pharma profits jab higher 13-Mar-2019 ShareCast
Wednesday preview: WA votes in Parliament, Hikma... 12-Mar-2019 ShareCast
Tobacco stocks rise after FDA boss Gottlieb quits 06-Mar-2019 ShareCast
Hikma launches generic Mitomycin injection in US 29-Jan-2019 ShareCast
Hikma 'thrilled' by US injectables contract win 03-Jan-2019 ShareCast
Hikma US launches generic version of Lundbeck's ... 10-Dec-2018 ShareCast
New management to reinvigorate Smith & Nephew, s... 10-Dec-2018 ShareCast
Jefferies downgrades NMC Health, ups Hikma 27-Nov-2018 ShareCast
Tuesday broker round-up 27-Nov-2018 ShareCast
Hikma in five-year licensing and supply agreemen... 27-Nov-2018 ShareCast
Tuesday broker round-up 20-Nov-2018 ShareCast
Hikma US launches generic version of Pfizer inso... 19-Nov-2018 ShareCast
Peel Hunt downgrades Hikma, says upgrades are in... 12-Nov-2018 ShareCast
Hikma raises FY guidance; signs Vectura inhaler ... 08-Nov-2018 ShareCast
Tuesday broker round-up 06-Nov-2018 ShareCast
Tuesday broker round-up 30-Oct-2018 ShareCast
Peel Hunt upgrades Hikma, says upgrade cycle wil... 16-Aug-2018 ShareCast
Thursday broker round-up 16-Aug-2018 ShareCast
Generics and injectables drive first half growth... 15-Aug-2018 ShareCast
Thursday broker round-up 09-Aug-2018 ShareCast
Hikma agrees MENA deal to distribute Perrigo's O... 09-Jul-2018 ShareCast
Tuesday broker round-up 03-Jul-2018 ShareCast
Sector movers: Pharma sector slumps on Pfizer 'b... 02-Jul-2018 ShareCast
Henriette Nielsen to lead 'transformation' at Hi... 04-Jun-2018 ShareCast
Friday broker round-up 18-May-2018 ShareCast

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

HIK Market Data

Currency UK Pounds
Share Price 1,939.00p
Change Today -2.00p
% Change -0.10 %
52 Week High 2,205.00p
52 Week Low 1,722.00p
Volume 34,783
Shares Issued 221.89m
Market Cap £4,302.36m
RiskGrade 125

HIK Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
50.99% below the market average50.99% below the market average50.99% below the market average50.99% below the market average50.99% below the market average
9.8% below the sector average9.8% below the sector average9.8% below the sector average9.8% below the sector average9.8% below the sector average
Price Trend
47.93% above the market average47.93% above the market average47.93% above the market average47.93% above the market average47.93% above the market average
69.81% above the sector average69.81% above the sector average69.81% above the sector average69.81% above the sector average69.81% above the sector average
Income
8.77% above the market average8.77% above the market average8.77% above the market average8.77% above the market average8.77% above the market average
75.00% above the sector average75.00% above the sector average75.00% above the sector average75.00% above the sector average75.00% above the sector average
Growth
32.44% below the market average32.44% below the market average32.44% below the market average32.44% below the market average32.44% below the market average
45.45% below the sector average45.45% below the sector average45.45% below the sector average45.45% below the sector average45.45% below the sector average

What The Brokers Say

Strong Buy 4
Buy 2
Neutral 4
Sell 1
Strong Sell 0
Total 11
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

HIK Dividends

  Latest Previous
  Final Interim
Ex-Div 21-Mar-24 10-Aug-23
Paid 03-May-24 15-Sep-23
Amount 47.00¢ 25.00¢

Trades for 26-Jun-2024

Time Volume / Share Price
11:25 18 @ 1,937.00p
11:25 5 @ 1,939.00p
11:25 19 @ 1,939.00p
11:25 36 @ 1,939.00p
11:25 148 @ 1,939.00p

HIK Key Personnel

CEO Riad Mishlawi

Top of Page